Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Rahat MA, Makhaik S, Hardy JA. Assessing Chikungunya Virus Protease Activity and Pharmacological Inhibition Using the acc-CHIK15-dnp Fluorogenic Peptide Substrate. Methods Mol Biol. 2027; 3067:125-147.
-
Sandmann M, Tajdar S, Sander S, Ruiz Carrillo D, Ganter B, Fischer C, Ocenas M, Etzold S, Pekarek N, Berger J, Meister TL, Selisko B, Canard B, Watt JM, Baszczy?ski O, Potter BV, Garcia Alai M, Tidow H, Pfefferle S, Meier C, Fliegert R. Design, structure-based optimization and antiviral evaluation of potent inhibitors for the macrodomain Mac1 of SARS-CoV-2. Nat Commun. 2026 07 27; 17(1).
-
Losos WR, Wang B, Fisher K, O'Connor L, Soni A, Gerber BS. Variation in Telehealth Use in a National Home Test-to-Treat Program for Acute Respiratory Infections. Telemed J E Health. 2026 Oct; 32(10):1029-1038.
-
Qaseem A, Obley AJ, Yost J, Abraham GM, Andrews RA, Jokela JA, Miller MC, Humphrey LL, Haeme R, Krain A, Poonacha T, Saini SD, Wilt TJ, Carroll K, Etxeandia-Ikobaltzeta I, Harrod CS, Shamliyan T, Vigna C. Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3). Ann Intern Med. 2026 Apr; 179(4):559-563.
-
Friedmann PD, Wilson D, de Gijsel D, Nolte K, Dejace J, Hoskinson R, Del Toro-Mejias L, Bianchet E, Dowd P, Soares WE, Stopka TJ. Mobile Telemedicine for Treating Chronic Hepatitis C Among Rural People Who Inject Drugs: A Randomized Clinical Trial. JAMA Netw Open. 2026 01 02; 9(1):e2555125.
-
Min EA, Bolduc P. Prevention and Management of Viral Hepatitis in Primary Care. Top Antivir Med. 2025 Dec; 33(6):711-726.
-
Maryam A, Moquin SA, Dovala D, Kaur J, Kurt Yilmaz N, Shaqra AM, Schiffer CA. Structural Analysis of Inhibitor Binding to the Feline Enteric Coronavirus (FECV) Main Protease. Viruses. 2025 Nov 16; 17(11).
-
Ding S, Yang D, Ullah I, Niu L, Unger M, Díaz-Salinas MA, Chandravanshi M, Zhou F, Beaudoin-Bussières G, Benlarbi M, Tolbert WD, Yoon K-W, Xu R, Laroche G, Gaudette F, Morton AJ, Lang ZC, Son A, Abrams C, Côté M, Smith AB, Huang RK, Matthies D, Munro JB, Pazgier M, Uchil PD, Finzi A. Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants. J Virol. 2025 11 25; 99(11):e0103425.
-
Ru Y, Ma-Lauer Y, Xiang C, Li P, von Brunn B, Richter A, Drosten C, Pichlmair A, Pfefferle S, Klein M, Damoiseaux RD, Betz UAK, von Brunn A. LMP7 as a Target for Coronavirus Therapy: Inhibition by Ixazomib and Interaction with SARS-CoV-2 Proteins Nsp13 and Nsp16. Pathogens. 2025 Sep 02; 14(9).
-
Lewis NM, Harker EJ, Grant LB, Zhu Y, Grijalva CG, Chappell JD, Rhoads JP, Baughman A, Casey JD, Blair PW, Jones ID, Johnson CA, Lauring AS, Gaglani M, Ghamande S, Columbus C, Steingrub JS, Shapiro NI, Duggal A, Busse LW, Felzer J, Prekker ME, Peltan ID, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Hough CL, Wilson JG, Mosier J, Qadir N, Chang SY, Ginde AA, Martinez A, Mohr NM, Mallow C, Harris ES, Johnson NJ, Srinivasan V, Gibbs KW, Kwon JH, Vaughn IA, Ramesh M, Safdar B, Goyal A, DeLamielleure LE, DeCuir J, Surie D, Dawood FS, Tenforde MW, Uyeki TM, Garg S, Ellington S, Self WH. Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study. Clin Infect Dis. 2025 08 01; 81(1):190-197.